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Background: Identifying patients with atrial ﬁbrillation (AF) using
administrative data is important for epidemiologic and outcomes
research. Although administrative data cover large populations, it is
necessary to assess their validity in identifying AF patients.
Methods:We used Ontario family physician electronic medical records
from the Electronic Medical Record Administrative data Linked Data-
base (EMRALD) as a reference standard to assess the accuracy of
administrative data algorithms in identifying patients with AF. From a
random sample of 7500 adult patients, patients with AF as recorded in
family physician records were identiﬁed.
Results: The optimal algorithm consisted of any of: hospitalization or
an emergency room code for AF or prescription for an AF-speciﬁc
antiarrhythmic agent or billing code for cardioversion, or prescription
for an anticoagulant that was accompanied by a physician billing code.Received for publication April 6, 2016. Accepted June 14, 2016.
Corresponding author: Dr Karen Tu, c/o ICES, G1 06, 2075 Bayview
Ave, Toronto, Ontario M4N 3M5, Canada. Tel.: þ1-416-480-4055 3871;
fax: þ1-416-480-6048.
E-mail: karen.tu@ices.on.ca
See page 1565 for disclosure information.
http://dx.doi.org/10.1016/j.cjca.2016.06.006
0828-282X/ 2016 The Authors. Published by Elsevier Inc. on behalf of the Canadia
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).RESUME
Introduction : L’identiﬁcation des patients atteints de ﬁbrillation
auriculaire (FA) à partir des donnees administratives est importante pour
la recherche epidemiologique et l’analyse de resultat. Bien que les
donnees administratives couvrent de vastes populations, il est necessaire
d’evaluer leur validite dans l’identiﬁcation des patients atteints de FA.
Methodes : Nous avons utilise les dossiers medicaux electroniques de
medecins de famille de l’Ontario qui proviennent de la banque de
donnees EMRALD (Electronic Medical Record Administrative data
Linked Database) comme etalon de reference pour evaluer
l’exactitude des algorithmes fondes sur les donnees administratives
dans l’identiﬁcation des patients atteints de FA. À partir d’un
echantillon aleatoire de 7500 patients adultes, nous avons identiﬁe les
patients atteints de FA d’après ce qui etait enregistre aux dossiers des
medecins de famille.Atrial ﬁbrillation (AF) is the most prevalent heart rhythm
disorder, particularly among the elderly population and con-
fers signiﬁcant effects on patient outcomes and health care
costs.1 A systematic review on AF using electronic medical
data reported that previous AF validation studies mostly used
older data, assessed populations that might not berepresentative of the general population, and had a dispro-
portionate focus on inpatient data.2 Studies that rely only on a
diagnosis of AF in the hospital discharge record might miss
many patients with AF who receive ambulatory medical care.
We sought to determine AF disease burden and patterns of
care over time using a validated algorithm incorporating in-
and outpatient administrative data.
Methods
The Electronic Medical Record Administrative data
Linked Database (EMRALD) held at the Institute for Clinical
Evaluative Sciences (ICES) was used as the reference standard
for the diagnosis of AF for the health administrative datan Cardiovascular Society. This is an open access article under the CC BY-NC-
for arrhythmia. The algorithm sensitivity was 80.7% (95% conﬁdence
interval [CI], 75.1-86.3), speciﬁcity 99.1% (95% CI, 98.9-99.3), positive
predictive value 71.1% (95% CI, 65.1-77.1), and negative predictive
value 99.5% (95% CI, 99.3-99.7). This algorithm, applied to the
Ontario population, resulted in a calculated increase in AF prevalence
from 1.68% to 2.36% over the years 2000-2014. Anticoagulation rates
for AF patients increased from 53% in 2011 to 60% in 2014. Among
AF patients receiving anticoagulants, novel oral anticoagulant utiliza-
tion increased from < 5% in 2011 to > 50% in 2014.
Conclusions: Identifying patients with AF can be done using admin-
istrative data, and the algorithm can be used to assess trends in dis-
ease burden over time and patterns of care in large populations.
Resultats : L’algorithme optimal consistait en : l’hospitalisation, ou le
code à la salle des urgences pour une FA ou la prescription d’un
antiarythmique speciﬁque de la FA ou le code de facturation con-
cernant une cardioversion, ou la prescription d’un anticoagulant qui
etait accompagnee d’un code de facturation du medecin concernant
une arythmie. La sensibilite de l’algorithme etait de 80,7 % (intervalle
de conﬁance [IC] à 95 %, 75,1-86,3), la speciﬁcite, de 99,1 % (IC à
95 %, 98,9-99,3), la valeur predictive positive, de 71,1 % (IC à 95 %,
65,1-77,1), et la valeur predictive negative, de 99,5 % (IC à 95 %, 99,3-
99,7). Cet algorithme, applique à la population de l’Ontario, entraînait
le calcul d’une augmentation dans la prevalence de la FA de 1,68 % à
2,36 % au cours des annees 2000 à 2014. Les taux d’anticoagulation
des patients atteints de FA augmentaient de 53 % en 2011 à 60 %
en 2014. Parmi les patients atteints de FA qui recevaient des
anticoagulants, l’utilisation du nouvel anticoagulant oral augmentait
de < 5 % en 2011 à > 50 % en 2014.
Conclusions : L’identiﬁcation des patients atteints de FA peut être
realisee à partir des donnees administratives, et l’algorithme peut
être utilise pour evaluer les tendances dans le fardeau de la
maladie au ﬁl du temps et les modèles de soins dans de vastes
populations.
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this article, including detailed validation procedures, addi-
tional display material, and a full reference list, see the
Supplementary Material.) EMRALD consists of all clinically
relevant information in the patient chart of volunteering
family physicians in Ontario using PS Suite (Telus Health,
Ottawa, ON) electronic medical record (EMR) and can be
linked to the health administrative data holdings for the
province of Ontario held at ICES.
The data used in the validation portion of this study were
extracted between June and November 2011. At the time of
the study the data in EMRALD were contributed by 83
primary care physicians who had been using their EMR for at
least 2 years and whose data met quality and completeness
standards.3 EMRALD patients and physicians are similar to all
Ontario patients and physicians for most characteristics.3
A random sample of 7500 adult patients aged 20 years or
older as of December 31, 2010 was drawn from 73,014 adult
patients of EMRALD physicians. Patients with persistent or
paroxysmal AF were identiﬁed using manual chart abstraction.
We used health administrative data comprised of hospi-
talizations, emergency department visits, physician billing,
and drug beneﬁts information. Hospital and emergency room
visits have coding speciﬁcally for AF, whereas the physician
billing code for AF is included in a general arrhythmia code.
Because of the ambiguous nature of AF diagnostic codes in
the physician billing database, we also tested procedure codes
for cardioversion (electrical and/or chemical; Z437) and
AF-related medications. Multiple algorithms using adminis-
trative data were examined, varying according to the admin-
istrative data sources used and the timeframe of the
assessment. For algorithms that included multiple physician
billings, a 30-day separation between billings was required.
The optimal algorithms were applied to the entire province
of Ontario, using the initial years as a ‘run-in’ period. We
calculated the crude, and age- and sex-standardized (to the
Census 1991 population), annual incidence and prevalence of
AF. Incident date was considered the date by which thepatient qualiﬁed as having AF as per the algorithm. All inci-
dent and prevalent cases were carried forward to the next year,
unless the patient died or moved out of the province.
Last, we assessed the proportion of patients using oral
anticoagulants measured in EMRALD from the patients
determined via chart abstraction to have AF, and in admin-
istrative data through the drug beneﬁt database. Patients
prescribed warfarin and a novel oral anticoagulant (NOAC;
apixaban, rivaroxaban, or dabigatran) were classiﬁed as
receiving whichever type was most recently prescribed. We
also examined the proportion of patients with AF who were
dispensed an oral anticoagulant in the province of Ontario
using our 2 most accurate administrative data algorithms: one
that used medications to identify AF patients and one that did
not, to assess for bias in anticoagulation rates using a case
identiﬁcation algorithm that included anticoagulants. Simi-
larly, we looked in the administrative data in ﬁscal year 2014
to assess changes in rates and types of anticoagulants
prescribed.
All data sets were linked using unique encoded identiﬁers
and all measures were calculated using the binomial approx-
imation method and analyses were conducted using SAS
version 9.2 (SAS Institute Inc, Cary, NC) at the ICES. This
study received ethics approval from the Sunnybrook Research
Ethics Board.Results
In the EMRALD cohort, 192 (2.6%) patients had AF. The
average age of the EMRALD cohort was 49.2 years (SD, 16.7
years) and the average age of the patients with AF was 74.1
years (SD, 11.6 years).
Using hospitalizations, emergency room visits, and physi-
cian billings for AF, an algorithm of a hospitalization or
emergency room record or 4 physician billing claims in 1 year
provided the best balance of sensitivity (70.8%) and positive
predictive value (70.8%), with excellent speciﬁcity (99.2%)
and negative predictive value (99.2%), while providing the
Figure 1. Crude and age- and sex-standardized atrial ﬁbrillation, 2000-2014. Bars represent crude numbers; points and lines represent age- and
sex-standardized prevalence and incidence rates.
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algorithm of 1 hospitalization, or an emergency room visit, or
AF-related medications, or cardioversion (without physician
billing codes), maximized sensitivity (80.7%) and positive
predictive value (71.1%) and provided high speciﬁcity
(99.1%) and negative predictive value (99.5%).
When these top-performing algorithms were applied to the
entire province of Ontario, the estimated annual age- and
sex-standardized prevalence and incidence (Fig. 1) for the
algorithm that included medications and cardioversion, and
the algorithm that included physician billings was < 1% and
< 0.5% higher, respectively, than just using hospitalizations
or emergency room visits. All algorithms resulted in a
consistent increase in prevalence over the past decade and a
half, with a highest adult prevalence estimate of 1.68% in
2000 to 2.36% in 2014. Incidence was relatively ﬂat using all
of the algorithms except for the algorithm that used medica-
tions and cardioversion, which showed a slight increase in
incidence in the past 3 years and ranged from a low of 2.48
per 1000 in 2008 to a high of 2.95 per 1000 in 2012.
Approximately two-thirds of the patients with AF in our
2011 EMRALD cohort were receiving anticoagulants, with >
90% of those patients being prescribed warfarin rather than a
NOAC (Table 1). These rates were similar when measured in
the administrative data compared with the EMR data (64.1%
vs 68.3% among the elderly patients) (Table 1). When we
compared the anticoagulation rates of patients with AF across
the province using our top 2 algorithms (one that included
anticoagulants to identify AF patients and one that did not),
we found that anticoagulation rates and proportion of
warfarin to NOAC use was similar regardless of the algorithmTable 1. Anticoagulation rates and types for adult patients with AF as ident
AF patients alive during
anticoagulation time
frame assessed
Fill
Anticoagulation rates in 2011 measured using the EMR
AF patients from 7500 chart abstraction
sample (age  20 years*)
188
AF patients from 7500 chart abstraction
sample (age  66 years*)
145
Anticoagulation rates in 2011 measured using administrative data
AF patients from 7500 chart abstraction
sample (age  66 years*)
145
AF in all of Ontario using rule 1 HOSP or 1
ED or 4 MD in 1 year (age  66 years*)
168,623 9
AF in all of Ontario using rule 1 HOSP or 1
ED or (1 anticoagulant medication and 1
MD) or 1 rhythm control medication or
(1 cardioversion claim and 1 MD) (age 
66 years*)
222,489 11
Anticoagulation rates in 2014 measured using administrative data
AF in all of Ontario using rule 1 HOSP or 1
ED or 4 MD in 1 year (age  66 yearsz)
192,374 11
AF in all of Ontario using rule 1 HOSP or 1
ED or (1 anticoagulant medication and 1
MD) or (1 rhythm control medication or
1 cardioversion claim and 1 MD) (age 
66 yearsz)
262,673 15
AF, atrial ﬁbrillation; ED, emergency room visit; EMR, electronic medical reco
anticoagulant.
* Age calculated as of December 31, 2010.
yExact numbers suppressed because of small cell size regulation.
zAge calculated as of December 31, 2013.used. The overall anticoagulation rates increased from 2011 to
2014 (53.8% to 60.8%), with an increase in the proportion of
anticoagulated patients ﬁlling a prescription for a NOAC from
< 5% in 2011 to 51.4% in 2014.Discussion
We found that patients with AF could be identiﬁed with a
reasonable degree of accuracy using administrative data. Our
anticoagulation rate measured in administrative data is in
keeping with previous ﬁndings whereby only approximately
half of the patients with AF are receiving anticoagulants.4
Because anticoagulant use was similar as measured in
EMRALD compared with administrative data on the same
cohort of patients, it appears that either data source would be
suitable to measure rates of anticoagulation and types of an-
ticoagulants used. Using administrative data in 2011, anti-
coagulation rates among AF patients was higher in EMRALD
(64.1%) compared with anticoagulation rates among AF
patients in the general population (53.8%). This higher rate
measured in EMRALD might be because our participating
physicians are more likely to prescribe anticoagulants or
because EMRALD captures prescriptions only whereas
administrative data captures medications actually dispensed.
Although the accuracy of our optimal algorithms were at
the lower end of positive predictive value and midrange for
sensitivity compared with other studies identifying AF pa-
tients from electronic medical data,2 the methods used in our
study might be more generalizable than that used in other
studies because our primary care reference standard popula-
tion is likely more reﬂective of the general population. Aiﬁed in EMR and administrative data
ed a prescription for
an anticoagulant
Filled a prescription
for warfarin
Filled a prescription
for a NOAC
n % n % n %
118 62.8 110 93.2 8 6.8
99 68.3 y < 98%y  5y < 7y
93 64.1 y < 98%y  5y < 7y
0,692 53.8 87,713 96.7 2979 3.3
8,793 53.4 113,901 95.9 4892 4.1
6,880 60.8 56,749 48.6 60,131 51.4
7,885 60.1 74,123 46.9 83,762 53.1
rd; HOSP, hospital claim; MD, physician billing claim; NOAC, novel oral
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prevalence of 3.0%.5 This higher prevalence than what we
found might be explained by their use of an electrocardiogram
database and by their deﬁnition of AF, which included a single
or transient episode, such as AF that occurred perioperatively.
However, there are some limitations to our reference
standard in that we were only able to identify patients with AF
who were recognized by physicians and although EMR re-
cords used met data quality and completeness standards,3 it is
possible that some information was missing. Additionally, our
anticoagulation rates might be underestimated because our
drug beneﬁt database is primarily for patients older than age
65 years, and NOACs require a limited use code for coverage
in the Ontario Drug Beneﬁt plan.
This work enables future studies to use administrative data
to measure changes in AF detection or treatment in large
populations or over time, and has the potential to be applied
in other provinces across Canada that have similar adminis-
trative databases.Acknowledgements
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